RxDoctor Payments Data

Steven Minter, DO

Internal Medicine · Columbia, SCNPI 1649431990

Payments from drug & device makers

$7,172in general payments, 2019–2025

Across 282 payments — averaging $25.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • E.r. Squibb & Sons, L.L.C.$487
  • Bristol Myers Squibb$388
  • Johnson & Johnson$360
  • Heron Therapeutics, Inc.$254
  • Astellas Pharma US Inc$236
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$5,93583%
  • Education$401%
  • Other$1,19617%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,172 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$5,937,389
Medicare patients
1,340
Services billed
321,984

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide41$694,449
PromactaEltrombopag Olamine17$411,745
BrukinsaZanubrutinib15$215,330
ErleadaApalutamide13$186,039
EliquisApixaban72$59,641
Imatinib Mesylate37$51,376
Abiraterone Acetate11$21,535
Letrozole306$6,369
Tamoxifen Citrate62$1,691
Anastrozole56$1,490
Exemestane16$1,216
Acyclovir101$1,210
Ondansetron OdtOndansetron58$1,181
Dexamethasone86$1,142
Hydroxyurea64$959

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$388$694,44941 claims
NovartisPromacta$2,456$411,74517 claims
Johnson & JohnsonErleada$360$186,03913 claims
PfizerEliquis$229$59,64172 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$119$21,53511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →